| abstract |
The present invention relates to a formulation for inhalation comprising a compound selected from a specific class of 5,6-dihydro-9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a] pyridine It relates to an inhalation formulation capable of delivering the compound to the lung as solid microparticles and the use of the formulation in the treatment of certain diseases, eg respiratory diseases. By using such a formulation, it is possible to eliminate the undesirable cough response associated with using these compounds in solution metered dose inhalers. This cough response prevents administration of a therapeutically effective dose and may compromise patient compliance in the long run. |